{"filing":{"accession_number":"0001654954-26-006705","cik":"0001131399","ticker":"GLAXF","company_name":"GSK plc","form":"6-K","filing_date":"2026-07-17","report_date":null,"primary_document":"a8188m.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1131399/000165495426006705/a8188m.htm"},"events":[{"id":18565,"run_id":16690,"accession_number":"0001654954-26-006705","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"GSK announces that its Phase III CALM-1 and CALM-2 trials for camlipixant in refractory chronic cough have yielded limited efficacy results, with CALM-1 meeting its primary endpoint but CALM-2 failing to reach statistical significance. Based on aggregate data, GSK has decided to discontinue further development of camlipixant in RCC. This is a material clinical development decision affecting a pipeline asset, but does not fit the specific event types (it is neither a discrete M\u0026A event, impairment charge, nor a results announcement). It is an operational/strategic decision to halt development of a drug candidate.","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-17","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":17410,"accession_number":"0001654954-26-006705","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"GSK announces that its Phase III CALM-1 and CALM-2 trials for camlipixant in refractory chronic cough have yielded limited efficacy results, with CALM-1 meeting its primary endpoint but CALM-2 failing to reach statistical significance. Based on aggregate data, GSK has decided to discontinue further development of camlipixant in RCC. This is a material clinical development decision affecting a pipeline asset, but does not fit the specific event types (it is neither a discrete M\u0026A event, impairment charge, nor a results announcement). It is an operational/strategic decision to halt development of a drug candidate.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-17T10:51:37.046155+00:00","company_name":"GSK plc","ticker":"GLAXF","filing_date":"2026-07-17"}]}